Severe dengue
Drug research and approvals for severe dengue: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 6 studies of severe dengue are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Gut Leakage' in DengueNCT07602920 · Not reported · University of Oxford · starts Aug 1, 2026
- International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)NCT07409857 · Not reported · Mahidol University · starts Dec 1, 2025
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell PatientsNCT07000747 · Not reported · Centre Hospitalier Universitaire de la Guadeloupe · starts Jun 24, 2024
- Innovative Multidisciplinary Strategies for Combating Severe DengueNCT06751836 · Not reported · Karolinska Institutet · starts Jan 3, 2025
- Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)NCT05631405 · Not applicable · Chulalongkorn University · starts Oct 16, 2022
Phase 3 3
- Diphtheria toxoidDiphtheria toxoid vaccine antigen
- Tetanus toxoidTetanus toxoid vaccine antigen
- Pertussis vaccine adsorbedBiological vaccine - induces immune response
Phase 2 4
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- AnakinraInterleukin-1 receptor antagonist
- IvermectinGlutamate-gated chloride channel modulator
- Mosnodenvir
Phase 1 or earlier 2
- ChloroquineFerriprotoporphyrin IX inhibitor
- BalapiravirRNA-directed RNA polymerase inhibitor
How its trials ended
51 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 90% met their primary endpoint, 5% missed it and 5% stopped early.
- Met its primary endpoint1937%
- Completed, result not reported1835%
- Ongoing1020%
- Status unknown24%
- Missed its primary endpoint12%
- Stopped: other or unclear12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA